Corcept Therapeutics

Intra-Cellular Therapies

Longboard Pharmaceuticals

Jazz Pharmaceuticals

Viatris

Bristol-Myers

Edgewise Therapeutics

Catalent

Elanco Animal Health Inc

Axsome Therapeutics

SPDR S&P Pharmaceuticals ETF

XPH tracks an equal-weighted index of US pharmaceutical companies.

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Q1 Earnings

GlaxoSmithKline

Johnson & Johnson

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Sanofi

The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.

Pharma In Transition: Context And Opportunities

Solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market.

Solid Q4 Earnings Fail to Impress Pharma ETFs

Amgen

Gilead Sciences

Eli Lilly

Novocure

United Therapeutics

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

7 Pharmaceutical Stocks That Could Make You Rich

Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

Bausch Health Companies Inc

Biogen

BioNTech SE

CRISPR Therapeutics

Moderna

Pfizer

Teva Pharmaceutical

Vertex Pharmaceuticals

With drug pricing reform on the horizon, investors may want to analyze their allocation.

Is Now the Time to Ditch Pharma Stocks?

According to the most recent healthcare report from the OECD, prescribed medicines here in the United States cost $1025.60 per capita, where the average per capita spending in the developed countries of the OECD is only $567.70. According to the same source, we spend $10,966 per capita on healthcare here in the United States versus a comparable country average of $5697 per capita elsewhere.

Dark Clouds On The Horizon For Big Pharma

Pharma ETFs Gain on Q2 Earnings

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Direxion Daily Healthcare Bull 3x Shares

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Healthcare Investors 

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

iShares U.S. Healthcare ETF

John Hancock Multifactor Healthcare ETF

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Global X Longevity Thematic ETF

Invesco Dynamic Biotechnology & Genome ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Pacer BioThreat ETF

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Global X Cannabis ETF

These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentration of buyers who have gathered around the same price level.

3 Pharmaceutical ETFs That Could Be Due For A Rebound

Virtus LifeSci Biotech Clinical Trials ETF

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

AbbVie

LeMaitre Vascular

The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets.

Healthcare: A Wide Choice Of Large And Well-Established Companies

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Pharma ETFs in Focus Post Q4 Earnings

Regeneron Pharmaceuticals

Zoetis

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives.

7 Pharmaceutical Stocks to Buy for 2021 and Beyond 

Invesco S&P SmallCap Health Care ETF

SPDR S&P Health Care Services ETF

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

3 Reasons to Bet on Healthcare ETFs

Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Q3 Earnings Fail to Impress Pharma ETFs

KraneShares MSCI All China Health Care Index ETF

The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.

Best Pharmaceutical ETFs for Q1 2021

CVS Health

Intuitive Surgical

Allscripts Healthcare Solutions

Smith & Nephew

Teladoc

These seven healthcare stocks may represent robust long-term investments no matter how reforms in the sector may develop post-election. The post 7 Healthcare Stocks That Can Survive Massive Reform appeared first on InvestorPlace.

7 Healthcare Stocks That Can Survive Massive Reform

Nearby support on the charts suggests that the pharmaceuticals sector could be one to watch over the last few months of 2020.

Pharma Stocks Poised to Move Higher

ARK Genomic Revolution Multi-Sector ETF

ALPS Medical Breakthroughs ETF

These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.

Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal

The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.

Best Pharmaceutical ETFs for Q4 2020

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Pharma ETFs Soar on Robust Q2 Earnings

President Donald Trump on Friday signed four executive orders aimed at lowering the high cost of prescription drugs in the United States in what would make sweeping changes to the prescription drug market in the U.S. if they are finalized.

Trump announces series of executive orders aimed at lowering drug costs

News for SPDR S&P Pharmaceuticals ETF ETF (XPH)